Galanin (1-30) (human)
Cat. No. 1179
Biological ActivityEndogenous peptide with multiple endocrine, metabolic and behavioral effects. Has been shown to have an action on intestinal smooth muscle, insulin and somatostatin release, and synaptic neurotransmission.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Niiro et al (1998) Mechanisms of galanin-induced contraction in the rat myometrium. Br.J.Pharmacol. 124 1623. PMID: 9756377.
Wang et al (1998) Hypothalamic galanin: control by signals of fat metabolism. Brain Res. 804 7. PMID: 9729239.
Schmidt et al (1991) Isolation and primary structure of pituitary human galanin, a 30-residue nonamidated neuropeptide. Proc.Natl.Acad.Sci.U.S.A. 88 11435. PMID: 1722333.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for Galanin (1-30) (human) include:
Chiu et al (2013) Bacteria activate sensory neurons that modulate pain and inflammation. Nature 501 52. PMID: 23965627.
Do you know of a great paper that uses Galanin (1-30) (human) from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Galanin (1-30) (human), supplier, Endogenous, galanin, agonists, GAL, GalR, Receptors, Galanin, Tocris Bioscience, Galanin Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Non-peptide apelin receptor agonistBML 111
FPR2 (lipoxin A4 receptor) agonistAmylin (rat)
Potent endogenous peptide agonist for amylin, calcitonin, CGRP and adrenomedullin receptorsCalcitonin (human)
Endogenous calcitonin receptor agonist; inhibits bone resorptionSpexin
Potent GAL2/3 agonist; exhibits anxiolytic effects in vivoMM 54
Potent apelin receptor antagonistMSG 606
Potent human MC1 receptor antagonist; also MC3 and MC5 partial agonist
March 18 - 22, 2017
Little Rock, ARK, USA